Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The study is designed to determine the effect of weekly intramuscular (IM) administration of
30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and
T2-weighted cranial magnetic resonance imaging (MRI) lesions in Chinese patients with
clinically diagnosed (using revised McDonald criteria) relapsing multiple sclerosis (MS).